Advanced Filters
noise

Vision Loss Clinical Trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 69 clinical trials

Featured trial
P Penn Presbyterian Medical Center

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis

This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United …

18-93 years All Phase 1
Featured trial
P Penn Presbyterian Medical Center

Pregabalin (Lyrica) in the Management of Oral Mucositis Pain in Head/Neck Chemoradiation Therapy Patients

Double-blind, randomized, single-center pilot study to assess the effectiveness of pregabalin (Lyrica) in the management of mucositis pain in head and neck cancer.

18 years and older All
Featured trial
P Penn Presbyterian Medical Center

A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects with Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)

The primary purpose of this study is to determine the therapeutic effectiveness of Ifetroban to improve sinus and nasal symptoms and quality of life in subjects with Aspirin Exacerbated Respiratory Disease (AERD).

18 years and older All Phase 2
Featured trial
P Penn Presbyterian Medical Center

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)

This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess …

18-80 years All Phase 3
Featured trial
M Mood & Anxiety Disorders Treatment & Research Program Psychiatry General Inbox

A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication AXS-05 (a combination of bupropion and dextromethorphan) compared to bupropion (Approved by FDA), in patients with depression who have not responded to prior treatment with at least one antidepressant. …

18-65 years All
Featured trial
P Penn Presbyterian Medical Center

The PATCH trial for patients Quarantined at Home (Prevention and Treatment of COVID-19 with hydroxychloroquine)

A double-blind placebo controlled trial of high dose hydroxychloroquine (HCQ) as a treatment for COVID-19 positive patients who are quarantined at home

18-95 years All Phase N/A
Featured trial
P Penn Presbyterian Medical Center

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

1 years and older All Phase 3
Featured trial
P Penn Presbyterian Medical Center

The PATCH trial for Healthcare Workers (Prevention and Treatment of COVID-19 with hydroxychloroquine)

The PATCH trial tests hydroxychloroquine as a treatment in patients with COVID-19 and a preventative medication in health care workers at high risk of contracting COVID-19. 

18-95 years All Phase N/A
P Penn Presbyterian Medical Center

Study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 subjects with Leber's Congenital Amourosis (LCA) Due to to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.

You are invited to take part in a research study for with the investigational drug, QR-110 (referred to as “the study drug”) for Leber's Congenital Amourosis . Currently there is no approved treatment for LCA10. The study drug is designed to repair the problem that causes LCA10. This may stop …

18-90 years All Phase N/A
C Carol Mcalear

A Randomized Double-Blind Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis

Please reference protocol section 2.

18-99 years All Phase 3

Simplify language using AI